Remus Pharmaceuticals Limited (NSE:REMUS)
India · Delayed Price · Currency is INR 856.25
+11.80 (1.40%)
Oct 7, 2026, 3:29 PM IST
Remus Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 10,090 | 7,320 | 13,192 | 10,163 | - | - | |
Market Cap Growth | 18.49% | -44.51% | 29.81% | - | - | - |
Enterprise Value | 10,179 | 7,469 | 13,164 | 10,212 | - | - |
Last Close Price | 844.45 | 627.58 | 1117.48 | 860.04 | - | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 26.90 | 19.79 | 45.38 | 49.53 | - | - |
PS Ratio | 1.17 | 0.86 | 2.13 | 4.77 | - | - |
PB Ratio | 2.57 | 1.89 | 4.67 | 5.80 | - | - |
P/TBV Ratio | 2.91 | 2.14 | 5.34 | 6.83 | - | - |
P/FCF Ratio | 277.19 | 203.90 | 439.73 | - | - | - |
P/OCF Ratio | 54.80 | 40.31 | 189.00 | 752.80 | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.18 | 0.88 | 2.12 | 4.80 | - | - |
EV/EBITDA Ratio | 17.65 | 13.34 | 28.75 | 35.56 | - | - |
EV/EBIT Ratio | 18.62 | 13.85 | 29.52 | 36.68 | - | - |
EV/FCF Ratio | 279.67 | 208.04 | 438.80 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.07 | 0.07 | 0.08 | 0.08 | 0.42 | 0.03 |
Debt / EBITDA Ratio | 0.48 | 0.48 | 0.49 | 0.49 | 0.71 | 0.04 |
Debt / FCF Ratio | 7.54 | 7.54 | 7.66 | - | 3.08 | 0.04 |
Net Debt / Equity Ratio | -0.07 | -0.07 | -0.01 | -0.06 | 0.26 | -0.14 |
Net Debt / EBITDA Ratio | -0.50 | -0.50 | -0.09 | -0.37 | 0.44 | -0.22 |
Net Debt / FCF Ratio | -7.75 | -7.75 | -1.43 | 5.53 | 1.90 | -0.19 |
Asset Turnover | 1.69 | 1.69 | 1.62 | 1.16 | 1.79 | 1.84 |
Inventory Turnover | 12.01 | 12.01 | 11.26 | 7.53 | 22.88 | 8.96 |
Quick Ratio | 1.31 | 1.31 | 1.11 | 0.99 | 0.97 | 0.44 |
Current Ratio | 1.98 | 1.98 | 1.82 | 1.51 | 1.39 | 0.84 |
Return on Equity (ROE) | 13.78% | 13.78% | 16.79% | 24.98% | 66.14% | 71.37% |
Return on Assets (ROA) | 6.67% | 6.67% | 7.28% | 9.46% | 26.40% | 19.63% |
Return on Invested Capital (ROIC) | 11.70% | 13.19% | 16.35% | 23.77% | 53.60% | 77.53% |
Return on Capital Employed (ROCE) | 12.60% | 12.60% | 14.30% | 14.50% | 40.30% | 63.30% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 6, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 3.72% | 5.05% | 2.20% | 2.02% | - | - |
FCF Yield | 0.36% | 0.49% | 0.23% | -0.19% | - | - |
Dividend Yield | 0.12% | 0.16% | 0.13% | 0.09% | - | - |
Payout Ratio | 1.59% | 3.19% | 4.06% | 2.88% | - | - |
Buyback Yield / Dilution | -100.00% | -100.00% | 47.86% | -38.35% | -2.10% | - |
Total Shareholder Return | -99.88% | -99.84% | 47.99% | -38.27% | -2.10% | - |